{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:05:47Z","timestamp":1759773947943,"version":"3.44.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.contraception.2020.05.010","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T11:18:29Z","timestamp":1590491909000},"page":"243-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduction in use of cyproterone\/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy"],"prefix":"10.1016","volume":"102","author":[{"given":"Fernie J.A.","family":"Penning-van Beest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene D.","family":"Bezemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Smits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis A.","family":"Garc\u00eda Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Cea Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Lapi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Asiimwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron M.C.","family":"Herings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2020.05.010_b0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2020.05.010_b0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001\u20139","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2020.05.010_b0015","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(01)06522-9","article-title":"Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives","volume":"358","author":"Vasilakis-Scaramozza","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2020.05.010_b0020","unstructured":"European Medicines Agency. Assessment report cyproterone acetate\/ethinylestradiol (2 mg\/0.035 mg) containing medicinal products. 2013."},{"key":"10.1016\/j.contraception.2020.05.010_b0025","unstructured":"EU PAS Register Number EUPAS8412 - Drug Utilization Study on Diane\u00ae-35 (and generics) in European healthcare databases. In: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)."},{"key":"10.1016\/j.contraception.2020.05.010_b0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.contraception.2016.10.003","article-title":"Prescribing of cyproterone acetate\/ethinylestradiol in UK general practice: a retrospective descriptive study using The Health Improvement Network","volume":"95","author":"Cea Soriano","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.05.010_b0035","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40261-017-0529-9","article-title":"Prescription appropriateness of cyproterone acetate\/ethinylestradiol in primary care: a population-based study in Italy","volume":"37","author":"Lapi","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.contraception.2020.05.010_b0040","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/pds.4319","article-title":"Thrombotic risk minimization for Diane-35 and generics","volume":"26","author":"Bezemer","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078242030158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001078242030158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:16:35Z","timestamp":1757880995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001078242030158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S001078242030158X"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2020.05.010","relation":{},"ISSN":["0010-7824"],"issn-type":[{"type":"print","value":"0010-7824"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction in use of cyproterone\/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2020.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}